Wang Jinkui, Yu Zhenlong, Wang Chao, Tian Xiangge, Huo Xiaokui, Wang Yan, Sun Chengpeng, Feng Lei, Ma Jing, Zhang Baojing, Yang Qining, Ma Xiaochi, Xu Yinghui
The First Affliated Hospital & Key Laboratory of Pharmacokinetic and Drug Transport of Liaoning, College of Pharmacy, Academy of Integrative Medicine, Dalian Medical UniversityDalian, 116044, China.
Key Laboratory of Digital Quality Evaluation of Chinese Material Medical of State Administration of TCM, Guangdong Pharmaceutical UniversityGuangdong, China.
Am J Cancer Res. 2017 Jun 1;7(6):1270-1284. eCollection 2017.
Dehydrocostus lactone (DHE), a natural sesquiterpene lactone, has been used for treatment of various diseases with its anti-inflammatory activity. Recently, it has caused extensive interest in researchers due to it has anti-cancer abilities in some types of carcinomas. However, the anti-cancer effect and mechanism of DHE in glioma remains unclear. The present study conducted to determine the biological effects of DHE on the glioblastoma cells, as well as the mechanisms underlying these effects. After treatment with DHE, the glioblastoma (U118, U251 or U87) cells were significantly inhibited in their viability, proliferation and migration. At the meantime, DHE also induced mitochondria-mediated apoptosis by promoting the release of cytochrome c into cytosol, which activating caspase signaling pathway. Furthermore, our results fully demonstrate that DHE significantly suppressed COX-2 expression by inhibiting the phosphorylation of IKKβ via targeting the ATP-binding site, thereby abrogating NF-κB binding and p300 recruitment to COX-2 promoter. Moreover, the current study firstly demonstrated that DHE can cross blood-brain barrier (BBB). In addition, treatment with DHE markedly inhibited neoplastic weight and volume without the notable adverse effects in the xenograft nude mice model, and these effects may be mediated through inhibition of the IKKβ/NF-κB/COX-2 signaling pathway. These findings provide the pharmacological evidence for development of DHE as a potential agent against glioma.
脱氢木香内酯(DHE)是一种天然倍半萜内酯,因其抗炎活性已被用于治疗多种疾病。最近,由于它在某些类型的癌症中具有抗癌能力,引起了研究人员的广泛关注。然而,DHE在胶质瘤中的抗癌作用及机制仍不清楚。本研究旨在确定DHE对胶质母细胞瘤细胞的生物学效应及其潜在机制。用DHE处理后,胶质母细胞瘤(U118、U251或U87)细胞的活力、增殖和迁移受到显著抑制。同时,DHE还通过促进细胞色素c释放到细胞质中诱导线粒体介导的凋亡,从而激活半胱天冬酶信号通路。此外,我们的结果充分表明,DHE通过靶向ATP结合位点抑制IKKβ的磷酸化,从而显著抑制COX-2的表达,进而消除NF-κB与COX-2启动子的结合及p300的募集。此外,本研究首次证明DHE可以穿越血脑屏障(BBB)。另外,在异种移植裸鼠模型中,用DHE治疗显著抑制肿瘤重量和体积,且无明显不良反应,这些作用可能是通过抑制IKKβ/NF-κB/COX-2信号通路介导的。这些发现为将DHE开发为一种潜在的抗胶质瘤药物提供了药理学证据。